Director, Clinical Research — RNAi Therapeutics Lead

Alnylam Pharmaceuticals, Inc.

Maidenhead

Presencial

GBP 190.000 - 258.000

Jornada completa

14 días+

Una candidatura completa en un minuto

Currículum y carta de presentación personalizados, listos para enviar.

Supera los filtros ATS

Descripción de la vacante

Alnylam Pharmaceuticals is seeking an imaginative physician drug developer to lead clinical programs across neurology and hematology. The Director will provide clinical leadership in developing RNAi therapeutics and drive progress from Phase 2 to Phase 3, reporting to the program strategy lead and collaborating with regulatory, biostatistics, clinical operations, preclinical, and medical affairs teams.

The role emphasizes serving as a development spokesperson at external meetings and regulatory

Formación

  • MD with strong research background or MD/PhD with best of class clinical and/or research training as shown through research support and peer-reviewed publications.

Responsabilidades

  • Be the subject matter expert for the relevant disease area(s).
  • Be the strategic leader providing a strong, clear voice for the clinical program.
  • Develop creative but realistic approaches to drug development and lead clinical efforts towards global regulatory approvals.
  • Oversight of trial conduct and safety.
  • Collaborate with Preclinical, Regulatory Affairs and Medical Affairs to ensure integrated development strategies.
  • Be accountable for all relevant timelines and deliverables.
  • Supervise major written deliverables and presentations.
  • Sign off on protocols, investigator brochures, and informed consent forms.
  • Influence internal and external audiences in a high impact, highly visible fashion.

Conocimientos

MD with research background
Neurology board certification
Clinical development experience

Educación

MD or MD/PhD

Descripción del empleo

Alnylam Pharmaceuticals is seeking an imaginative physician drug developer to lead clinical programs across neurology and hematology. The Director will provide clinical leadership in developing RNAi therapeutics and drive progress from Phase 2 to Phase 3, reporting to the program strategy lead and collaborating with regulatory, biostatistics, clinical operations, preclinical, and medical affairs teams.

The role emphasizes serving as a development spokesperson at external meetings and regulatory

Consigue la evaluación confidencial y gratuita de tu currículum.

o arrastra y suelta tu archivo aquí

Similar jobs

Puestos de trabajo similares que vale la pena comparar

Strategic Director, Clinical Research — RNAi Therapeutics
Strategic Director, Clinical Research — RNAi Therapeutics

Alnylam • Maidenhead

Presencial
GBP 90.000 - 180.000
Director, Clinical Research- Benign Hematology
Director, Clinical Research- Benign Hematology

Alnylam • Maidenhead

Presencial
GBP 90.000 - 180.000
Executive Director, Clinical Research - Neurodegeneration
Executive Director, Clinical Research - Neurodegeneration

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 189.000 - 303.000
Hybrid Exec Director, Clinical Research - Neurodegeneration
Hybrid Exec Director, Clinical Research - Neurodegeneration

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 189.000 - 303.000
Sr. Manager, Regulatory Affairs
Sr. Manager, Regulatory Affairs

Alnylam Pharmaceuticals, Inc. • Maidenhead

Presencial
GBP 90.000 - 120.000
Senior Manager, R&D Quality Assurance
Senior Manager, R&D Quality Assurance

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 110.000 - 150.000
Senior Manager, R&D Quality Assurance
Senior Manager, R&D Quality Assurance

Alnylam • Maidenhead

Híbrido
GBP 95.000 - 130.000
Associate Director, Biostatistics
Associate Director, Biostatistics

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 95.000 - 140.000
Associate Director, Biostatistics
Associate Director, Biostatistics

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 120.000 - 160.000
Senior R&D QA Lead: Clinical Trials & Inspection Readiness
Senior R&D QA Lead: Clinical Trials & Inspection Readiness

Alnylam Pharmaceuticals, Inc. • Maidenhead

Híbrido
GBP 110.000 - 150.000